AC Immune (ACIU) Common Equity (2014 - 2026)
AC Immune (ACIU) posted quarterly Common Equity of $40.3 billion for Q1 2026, up 38091.77% year-over-year from N/an in Q1 2025, and down 28.29% quarter-over-quarter from $56.2 billion in Q4 2025.
AC Immune (ACIU) Common Equity (2014 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Common Equity for 13 consecutive years, with $40.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 38091.77% year-over-year to $40.3 billion; the TTM figure through Mar 2026 stood at $40.3 billion (up 38091.77% YoY), while the FY2025 annual figure was $54.1 billion, up 42141.29% from the prior year.
- Common Equity retreated to $40.3 billion in Q1 2026 per ACIU's latest filing, from $56.2 billion in the prior quarter.
- Across five years, Common Equity topped out at $231.9 billion in Q1 2022 and bottomed at $78.1 million in Q3 2025.
- Historically, Common Equity has averaged $19.4 billion across 5 years, with a median of $165.3 million in 2023.
- Annual changes were most pronounced in 2023 — Common Equity sank 99.93% — and 2025, when it soared 43718.74%.
- AC Immune's Common Equity stood at $175.4 million in 2022, then rose by 3.24% to $181.1 million in 2023, then fell by 29.23% to $128.2 million in 2024, then jumped by 43718.74% to $56.2 billion in 2025, then dropped by 28.29% to $40.3 billion in 2026.
- Business Quant data shows ACIU's Common Equity at $40.3 billion in Q1 2026, $56.2 billion in Q4 2025, and $78.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 44.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.50 Mn |
| Mar 31, 2026 | 40.27 Bn |
| Dec 31, 2025 | 56.16 Bn |
| Sep 30, 2025 | 78.06 Mn |
| Jun 30, 2025 | 90.28 Mn |
| Mar 31, 2025 | 105.44 Mn |
| Dec 31, 2024 | 128.16 Mn |
| Sep 30, 2024 | 150.24 Mn |
| Jun 30, 2024 | 136.48 Mn |
| Mar 31, 2024 | 165.76 Mn |
| Dec 31, 2023 | 181.10 Mn |
| Sep 30, 2023 | 142.27 Mn |
| Jun 30, 2023 | 154.96 Mn |
| Mar 31, 2023 | 165.35 Mn |
| Dec 31, 2022 | 175.42 Mn |
| Sep 30, 2022 | 196.79 Mn |
| Jun 30, 2022 | 210.58 Mn |
| Mar 31, 2022 | 231.86 Bn |
| Dec 31, 2021 | 251.58 Mn |
| Sep 30, 2021 | 195.19 Mn |